PTO/SB/08A and B (08-03)
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Substitute for Form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

	APPLICATION NO.:	FILING DATE:
	09/825,920	April 3, 2001
FIRST NAMED INVENTOR:		ART UNIT:
	Robert G. Udell	1655
	EXAMINER NAME:	ATTY. DOCKET NO.:
	WINSTON, Randall O.	33346/US/2

U.S. PATENT DOCUMENTS					
EXAMINER INITIALS*	Cite No.	PATENT NUMBER Number – Kind Code <sup>2</sup> (if known)	ISSUE DATE MM-DD-YYYY	Name of Patentee of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	3,950,319	04/1976	Schmidt et al.	
	2.	4,010,258	03/1977	Murao	
	3.	4,343,816	08/1982	Cavazza	
	4.	4,687,782	08/1987	Brantman	
	5.	4,921,475	05/1990	Sibalis	
	6.	5,008,110	04/1991	Benecke et al.	
	7.	5,030,458	07/1991	Shug et al.	
	8.	5,030,657	07/1991	Burtle et al.	
	9.	5.087,240	02/1992	Sibalis	
	10.	5,088,977	02/1992	Sibalis	
	11.	5,163,899	11/1992	Sibalis	
	12.	5,164,189	11/1992	Farhadieh et al.	
	13.	5,240,961	08/1993	Shug	
	14.	5,254,346	10/1993	Tucker et al.	
	15.	5,290,561	03/1994	Farhadieh et al.	
	16.	5,332,213	07/1994	Klose, deceased	
	17.	5,336,168	08/1994	Sibalis	
	18.	5,352,456	10/1994	Fallon et al.	
	19.	5,362,753	11/1994	Blum et al.	
	20.	5,391,550	02/1995	Carniglia et al.	
	21.	5,407,713	04/1995	Wilfong et al.	
	22.	5,504,072	04/1996	Schmidl et al.	
	23.	5,560,928	10/1996	DeFelice	
	24.	5,634,874	07/1997	Bremer et al.	
	25.	6,200,569	03/2001	Cheng	
	26.	6,200,958	03/2001	Odaka et al.	
	27.	6,572,897	06/2003	Gorsek	
	28.	6,616,942	09/2003	Udell et al.	
	29.	6,893,627	05/2005	Ribnicky et al.	

PTO/SB/08A and B (08-03)	APPLICATION NO.:	FILING DATE:
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF CO Substitute for Form 1449A/PTO	09/825,920	April 3, 2001
INFORMATION DISCLOSURE	FIRST NAMED INVENTOR:	ART UNIT:
STATEMENT BY APPLICANT	Robert G. Udell	1655
	EXAMINER NAME:	ATTY. DOCKET NO.:
(Use as many sheets as necessary)	WINSTON, Randall O.	33346/US/2

U.S. PUBLICATION DOCUMENTS					
EXAMINER INITIALS*	Cite No.1	PUBLICATION NUMBER Number – Kind Code <sup>2</sup> (If Known)	NUMBER DATE  per – Kind Code <sup>2</sup> MM-DD-YYYY	Name of Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	30.	2001/0000474	12/2000	Matsuyama	
	31.	2002/0018818	02/2002	Suzuki et al.	
	32.	2003/0072822	04/2003	Ribnicky et al.	
	33.	2003/0161903	08/2003	Konishi et al.	
	34.	2003/082168	05/2003	Yegorva	
	35.	2004/0072906	04/2004	Udell et al.	
	36.	2004/0146539	07/2004	Gupta	
	37.	2004/091554	05/2004	Murray et al.	
	38.	2006/0051435	03/2006	Udell et al.	
	39.	2008/0152705	06/2008	Udell et al.	

	FOREIGN PATENT DOCUMENTS					
EXAMINER INITIALS	Cite No.1		PUBLICATION DATE	Name of Patentee or Applicant of Cited	Pages, Columns, Lines, Where Relevant Passages	T <sup>6</sup>
		Country Code <sup>3</sup> – Number <sup>4</sup> – Kind Code <sup>5</sup> (if known)	MM-DD-YYYY	Document	or Relevant Figures Appear	
	40.	EP 1166790	01/2002	Ito En, Ltd.		
	41.	EP 1174416	01/2002	Kabushiki Kaisha Yakult Honsha	0	

NON PATENT LITERATURE DOCUMENTS					
EXAMINER INITIALS O. Include name of Author (in CAPITAL LETTERS), title of the article (when appropriate), title of title (hook, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			т°		
	42.	AUTHOR UNKNOWN, "Glucosol™ Introduction," Soft Gel Technologies, Inc. Informational Pamphlet, date unknown, at least as early as April 3, 2001, Los Angeles, California, 9 pages			
	43.	AUTHOR UNKNOWN, "Glucosol™ Clinical Study Synopsis," American Study on Balancing Blood Sugar Levels with Glucosol™, Soft Gel Technologies, Inc., date unknown, at least as early as April 3, 2001, Los Angeles, California, 9 pages			
	44.	AUTHOR UNKNOWN, "Glucosol™ Case Study Results," American Case Study on Balancing Blood Sugar Levels with Glucosol™, Soft Gel Technologies, Inc., date unknown, at least as early as April 3, 2001, Los Angeles, California, 4 pages			

PTO/SB/08A and B (08-03)
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Substitute for Form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

APPLICATION NO.:	FILING DATE:		
09/825,920	April 3, 2001		
FIRST NAMED INVENTOR:	ART UNIT:		
Robert G. Udell	1655		
EXAMINER NAME:	ATTY. DOCKET NO.:		
WINSTON, Randall O.	33346/US/2		

NON PATENT LITERATURE DOCUMENTS				
45.	AUTHOR UNKNOWN, "Glucosol Clinical Study Results," Presented by Chemco Industries, Inc., date unknown, at least as early as April 3, 2001, 3 pages			
46.	BLANKSON, et al., "Conjugated Linoleic Acid Reduces Body Fat Mass in Overweight and Obese Humans," American Society for Nutritional Sciences, <i>J. Nutr.</i> , 2000, Vol 130, pp. 2943-2948			
47.	DELANY, et al., "Conjugated linoleic acid rapidly reduces body fat content in mice without affecting energy intake," <i>Am. J. Physiol.</i> , 1999, Vol. 276, pp. R1172-R1179			
48.	HAYASHI, et al., "Ellagitannins from <i>Lagerstroemia speciosa</i> as Activators of Glucose Transport in Fat Cells," <i>Planta Med.</i> , 2002, Vol. 68, pp. 173-175			
49.	JUDY, et al., "Antidiabetic activity of a standardized extract (Glucosol™) from Lagerstroemia speciosa leaves in Type II diabetics. A dose-dependence study," Journal of Ethnopharmacology, 2003, Vol. 87, pp. 115-117			
50.	KAKUDA, et al., Hypoglycemic Effect of Extracts from Lagerstroemia speciosa L. Leaves in Genetically Diabetic KK-AY Mice" Bioscience, Biotechnology and Biochemistry, 1996, Vol. 60, No. 2, pp. 204-208			
51.	LIU, et al., "An Extract of Lagerstroemia speciosa L. Has Insulin-Like Glucose Update-Stimulatory and Adipocyte Differentiation-Inhibitory Activities in 3T3-L1 Cells," Journal of Nutrition, 2001, Vol. 131, pp. 2242-2247			
52.	MURAKAMI, et al., "Screening of Plant Constituents for Effect on Glucose Transport Activity in Erhlich Ascites Tumour Cells," <i>Chem. Pharm. Bull.</i> , 1993, Vol. 41, No. 12, pp. 2129-2131			
53.	PARIZA, et al., "Conjugated Linoleic Acid and the Control of Cancer and Obesity,"  Toxicological Sciences, 1999, Vol. 52 (Supplement), pp. 107-110			
54.	PARK, et al., " Effect of Conjugated Linoleic Acid on Body Composition in Mice," Lipids, 1997, Vol. 32, No. 8, pp. 853-858			
55.	RISERUS, et al., "Conjugated linoleic acid (CLA) reduced abdominal adipose tissue in obese middle-aged men with signs of the metabolic syndrome: a randomised controlled trial," <i>International Journal of Obesity</i> , 2001, vol. 25, pp. 1129-1135			
56.	SMEDMAN, et al., "Conjugated Linoleic Acid Supplementation in HumansMetabolic Effects," <i>Lipids</i> , 2001, Vol. 36, No. 8, pp. 773-781			
57.	SUZUKI, et al., "Antiobesity Activity of Extracts from Lagerstroemia Speciosa L. Leaves on Female KK-AY Mice," J. Nutr. Sci. Vitaminol., 1999, Vol. 45, pp. 791-795			
58.	UDANI, et al., "Blocking Carbohydrate Absorption and Weight Loss: A Clinical Trial Using Phase 2™ Brand Proprietary Fractionated White Bean Extract," <i>Alternative Medicine Review</i> , 2004, Vol. 9, No. 1, pp. 63-69			

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation number (optionsi). See Kinds Codes of USPTO Patent Documents at www.uspto gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial anumber of the patent occurrent. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. Applicant is to place a chock mark here if English language Translation is attached.